Blood eosinophils in COPD: are biologics for everyone?
Therapeutic Advances in Respiratory Disease · 2026
DOI: 10.1177/17534666261471839 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2026. Verfasst von Marco Vanetti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Via Crotto Roncaccio 16, Tradate 21049, Italy. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Eosinophils, Biological Products. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ministero della salute.
Themen: COPD
Abstract (Originalsprache)
Background
Type 2 (T2) biologics represent a promising treatment option for chronic obstructive pulmonary disease (COPD) patients with eosinophilic inflammation.
Objectives
To evaluate the prevalence of stable COPD patients who may be eligible for T2 biologics.
Design
Real-world, retrospective, monocentric study in COPD patients undergoing inpatient pulmonary rehabilitation.
Methods
Clinical, functional, and inflammatory data were collected. Patients were considered eligible for T2 biologic therapy whether they were receiving optimized inhaled therapy and had a history of ⩾2 moderate and/or ⩾1 severe exacerbations in the previous year, together with a blood eosinophil count ⩾300 cells/μL.
Results
Among 441 patients, 21.5% had blood eosinophil counts ⩾300 cells/μL and 6.8% fulfilled the combined eligibility criteria. A high burden of respiratory and cardiometabolic comorbidities and increased cardiovascular risk was observed in the overall population.
Conclusion
Only a subgroup of patients seems eligible for biologics, treatment escalation should be based on optimized standard care management and patient phenotyping
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Via Crotto Roncaccio 16, Tradate 21049, Italy.
- Department of Medicine and Surgery, University of Insubria, via Ravasi 2, Varese 21100, Italy.
- Department of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.
- Department of Medicine and Surgery, University of Insubria, Varese, Italy.
- Allergy and Immunology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
ORCID-Profile: Marco Vanetti, Dina Visca, Francesco Ardesi
Förderung
- ministero della salute
Zitieren
APA
Vanetti, M., Visca, D., Ardesi, F., Taglioretti, A. M., Zappa, M., Pignatti, P., & Spanevello, A. (2026). Blood eosinophils in COPD: are biologics for everyone?. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666261471839
Vancouver
Vanetti M, Visca D, Ardesi F, Taglioretti AM, Zappa M, Pignatti P, et al. Blood eosinophils in COPD: are biologics for everyone?. Therapeutic Advances in Respiratory Disease. 2026. doi:10.1177/17534666261471839
BibTeX
@article{Vanetti2026,
author = {Vanetti, Marco and Visca, Dina and Ardesi, Francesco and Taglioretti, Antonia M and Zappa, Martina and Pignatti, Patrizia and Spanevello, Antonio},
title = {Blood eosinophils in COPD: are biologics for everyone?},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2026},
doi = {10.1177/17534666261471839}
}
EUVIMED